Compare BRTX & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | ERNA |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.0M |
| IPO Year | 2015 | 2021 |
| Metric | BRTX | ERNA |
|---|---|---|
| Price | $0.22 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.08 | 20.10 |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $582,000.00 |
| Revenue This Year | $24.64 | N/A |
| Revenue Next Year | $287.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 755.88 |
| 52 Week Low | $0.19 | $0.15 |
| 52 Week High | $2.10 | $3.00 |
| Indicator | BRTX | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 19.51 | 26.77 |
| Support Level | $0.19 | $0.27 |
| Resistance Level | $0.29 | $0.40 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 24.98 | 15.05 |
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.